Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claim 1-2 are pending
The non-final action filed on 10/17/2025 is vacated and withdrawn. Applicants arguments date d1/12/2026 is found to be persuasive. The anticipation rejection over Su et al. is hereby withdrawn.
Priority
This application is a continuation Application of International Application No. PCT/CN2025/079990, filed February 28, 2025, which claims priorities of Chinese Patent Application No. 202410234745.8, filed March 1, 2024, and Chinese Patent Application No. 202510219066.8, filed February 26, 2025.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-2 are rejected under 35 U.S.C. 102 (a) (1) and under 35 U.S.C 102(a)(2) as being anticipated by Gan et al. (WO 2024/235165 and its English equivalent AU 2024271467 (provided as NPL) priority date: 5/12/2023. 9/22/2023, 11/17/2023, 1/8/2024 and 2/1/2024)
Instant claims are drawn A compound and a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of (R)-N-(8-(7-fluoro-1-methyl-2- oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3,4-dihydro-2H-pyrano[3,2-c]pyridin-4-yl-4- d)propionamide and (R)-N-(8-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6- yl)-3,4-dihydro-2H-pyrano[3,2-c]pyridin-4-yl)propionamide (of the following structures) and a pharmaceutical composition comprising these compounds and a pharmaceutically acceptable excipient.
Compound 4 and Compound 8 from the instant disclosure.
PNG
media_image1.png
337
223
media_image1.png
Greyscale
PNG
media_image2.png
350
238
media_image2.png
Greyscale
Gan et al. discloses nitrogen-containing heterocyclic compounds which includes the instantly claimed compounds ([0260], page 38, 7th row, 3rd compound, Claim 22, page 168 , 5th row,2nd compound)
PNG
media_image3.png
111
200
media_image3.png
Greyscale
PNG
media_image4.png
120
204
media_image4.png
Greyscale
They further provides a use of the above compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease associated with an aldosterone synthase inhibitor [0261]. They disclose their compounds prepared for oral administration comprising 20% PEG400, 10% solutol and 70% water which anticipates the pharmaceutical composition claimed in instant claim 2
Therefore the compounds and composition disclosed by Gan et al. fully anticipates instant claims 1-2.
Conclusion
Claims 1-2 are rejected. No claims are allowed
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAVITHA RAO whose telephone number is (571)270-5315. The examiner can normally be reached on Mon-Fri 7 am to 4 pm..
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Dierdre (Renee) Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SAVITHA M RAO/Primary Examiner, Art Unit 1691